Exploratory IND Guidance Emphasizes FDA Flexibility On Data Requirements
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency believes that industry has not taken full advantage of the flexibility provided in investigational new drug regulations. The draft guidance advises sponsors on how to proceed with early Phase I, short-term "microdosing" studies.